Inhibitors of SARS-CoV entry--identification using an internally-controlled dual envelope pseudovirion assay.
Identifieur interne : 001483 ( PubMed/Corpus ); précédent : 001482; suivant : 001484Inhibitors of SARS-CoV entry--identification using an internally-controlled dual envelope pseudovirion assay.
Auteurs : Yanchen Zhou ; Juliet Agudelo ; Kai Lu ; David H. Goetz ; Elizabeth Hansell ; Yen Ting Chen ; William R. Roush ; James Mckerrow ; Charles S. Craik ; Sean M. Amberg ; Graham SimmonsSource :
- Antiviral research [ 1872-9096 ] ; 2011.
English descriptors
- KwdEn :
- Antiviral Agents (pharmacology), Drug Evaluation, Preclinical (methods), Drug Evaluation, Preclinical (standards), High-Throughput Screening Assays (methods), High-Throughput Screening Assays (standards), Humans, Microbial Sensitivity Tests (methods), Microbial Sensitivity Tests (standards), SARS Virus (drug effects), Virus Cultivation (methods), Virus Cultivation (standards), Virus Internalization (drug effects).
- MESH :
- chemical , pharmacology : Antiviral Agents.
- drug effects : SARS Virus, Virus Internalization.
- methods : Drug Evaluation, Preclinical, High-Throughput Screening Assays, Microbial Sensitivity Tests, Virus Cultivation.
- standards : Drug Evaluation, Preclinical, High-Throughput Screening Assays, Microbial Sensitivity Tests, Virus Cultivation.
- Humans.
Abstract
Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) emerged as the causal agent of an endemic atypical pneumonia, infecting thousands of people worldwide. Although a number of promising potential vaccines and therapeutic agents for SARS-CoV have been described, no effective antiviral drug against SARS-CoV is currently available. The intricate, sequential nature of the viral entry process provides multiple valid targets for drug development. Here, we describe a rapid and safe cell-based high-throughput screening system, dual envelope pseudovirion (DEP) assay, for specifically screening inhibitors of viral entry. The assay system employs a novel dual envelope strategy, using lentiviral pseudovirions as targets whose entry is driven by the SARS-CoV Spike glycoprotein. A second, unrelated viral envelope is used as an internal control to reduce the number of false positives. As an example of the power of this assay a class of inhibitors is reported with the potential to inhibit SARS-CoV at two steps of the replication cycle, viral entry and particle assembly. This assay system can be easily adapted to screen entry inhibitors against other viruses with the careful selection of matching partner virus envelopes.
DOI: 10.1016/j.antiviral.2011.07.016
PubMed: 21820471
Links to Exploration step
pubmed:21820471Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Inhibitors of SARS-CoV entry--identification using an internally-controlled dual envelope pseudovirion assay.</title><author><name sortKey="Zhou, Yanchen" sort="Zhou, Yanchen" uniqKey="Zhou Y" first="Yanchen" last="Zhou">Yanchen Zhou</name><affiliation><nlm:affiliation>Blood Systems Research Institute, University of California, San Francisco, CA 94118, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Agudelo, Juliet" sort="Agudelo, Juliet" uniqKey="Agudelo J" first="Juliet" last="Agudelo">Juliet Agudelo</name></author><author><name sortKey="Lu, Kai" sort="Lu, Kai" uniqKey="Lu K" first="Kai" last="Lu">Kai Lu</name></author><author><name sortKey="Goetz, David H" sort="Goetz, David H" uniqKey="Goetz D" first="David H" last="Goetz">David H. Goetz</name></author><author><name sortKey="Hansell, Elizabeth" sort="Hansell, Elizabeth" uniqKey="Hansell E" first="Elizabeth" last="Hansell">Elizabeth Hansell</name></author><author><name sortKey="Chen, Yen Ting" sort="Chen, Yen Ting" uniqKey="Chen Y" first="Yen Ting" last="Chen">Yen Ting Chen</name></author><author><name sortKey="Roush, William R" sort="Roush, William R" uniqKey="Roush W" first="William R" last="Roush">William R. Roush</name></author><author><name sortKey="Mckerrow, James" sort="Mckerrow, James" uniqKey="Mckerrow J" first="James" last="Mckerrow">James Mckerrow</name></author><author><name sortKey="Craik, Charles S" sort="Craik, Charles S" uniqKey="Craik C" first="Charles S" last="Craik">Charles S. Craik</name></author><author><name sortKey="Amberg, Sean M" sort="Amberg, Sean M" uniqKey="Amberg S" first="Sean M" last="Amberg">Sean M. Amberg</name></author><author><name sortKey="Simmons, Graham" sort="Simmons, Graham" uniqKey="Simmons G" first="Graham" last="Simmons">Graham Simmons</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21820471</idno><idno type="pmid">21820471</idno><idno type="doi">10.1016/j.antiviral.2011.07.016</idno><idno type="wicri:Area/PubMed/Corpus">001483</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001483</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Inhibitors of SARS-CoV entry--identification using an internally-controlled dual envelope pseudovirion assay.</title><author><name sortKey="Zhou, Yanchen" sort="Zhou, Yanchen" uniqKey="Zhou Y" first="Yanchen" last="Zhou">Yanchen Zhou</name><affiliation><nlm:affiliation>Blood Systems Research Institute, University of California, San Francisco, CA 94118, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Agudelo, Juliet" sort="Agudelo, Juliet" uniqKey="Agudelo J" first="Juliet" last="Agudelo">Juliet Agudelo</name></author><author><name sortKey="Lu, Kai" sort="Lu, Kai" uniqKey="Lu K" first="Kai" last="Lu">Kai Lu</name></author><author><name sortKey="Goetz, David H" sort="Goetz, David H" uniqKey="Goetz D" first="David H" last="Goetz">David H. Goetz</name></author><author><name sortKey="Hansell, Elizabeth" sort="Hansell, Elizabeth" uniqKey="Hansell E" first="Elizabeth" last="Hansell">Elizabeth Hansell</name></author><author><name sortKey="Chen, Yen Ting" sort="Chen, Yen Ting" uniqKey="Chen Y" first="Yen Ting" last="Chen">Yen Ting Chen</name></author><author><name sortKey="Roush, William R" sort="Roush, William R" uniqKey="Roush W" first="William R" last="Roush">William R. Roush</name></author><author><name sortKey="Mckerrow, James" sort="Mckerrow, James" uniqKey="Mckerrow J" first="James" last="Mckerrow">James Mckerrow</name></author><author><name sortKey="Craik, Charles S" sort="Craik, Charles S" uniqKey="Craik C" first="Charles S" last="Craik">Charles S. Craik</name></author><author><name sortKey="Amberg, Sean M" sort="Amberg, Sean M" uniqKey="Amberg S" first="Sean M" last="Amberg">Sean M. Amberg</name></author><author><name sortKey="Simmons, Graham" sort="Simmons, Graham" uniqKey="Simmons G" first="Graham" last="Simmons">Graham Simmons</name></author></analytic><series><title level="j">Antiviral research</title><idno type="eISSN">1872-9096</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (pharmacology)</term><term>Drug Evaluation, Preclinical (methods)</term><term>Drug Evaluation, Preclinical (standards)</term><term>High-Throughput Screening Assays (methods)</term><term>High-Throughput Screening Assays (standards)</term><term>Humans</term><term>Microbial Sensitivity Tests (methods)</term><term>Microbial Sensitivity Tests (standards)</term><term>SARS Virus (drug effects)</term><term>Virus Cultivation (methods)</term><term>Virus Cultivation (standards)</term><term>Virus Internalization (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term><term>Virus Internalization</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Evaluation, Preclinical</term><term>High-Throughput Screening Assays</term><term>Microbial Sensitivity Tests</term><term>Virus Cultivation</term></keywords><keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Drug Evaluation, Preclinical</term><term>High-Throughput Screening Assays</term><term>Microbial Sensitivity Tests</term><term>Virus Cultivation</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) emerged as the causal agent of an endemic atypical pneumonia, infecting thousands of people worldwide. Although a number of promising potential vaccines and therapeutic agents for SARS-CoV have been described, no effective antiviral drug against SARS-CoV is currently available. The intricate, sequential nature of the viral entry process provides multiple valid targets for drug development. Here, we describe a rapid and safe cell-based high-throughput screening system, dual envelope pseudovirion (DEP) assay, for specifically screening inhibitors of viral entry. The assay system employs a novel dual envelope strategy, using lentiviral pseudovirions as targets whose entry is driven by the SARS-CoV Spike glycoprotein. A second, unrelated viral envelope is used as an internal control to reduce the number of false positives. As an example of the power of this assay a class of inhibitors is reported with the potential to inhibit SARS-CoV at two steps of the replication cycle, viral entry and particle assembly. This assay system can be easily adapted to screen entry inhibitors against other viruses with the careful selection of matching partner virus envelopes.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21820471</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9096</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Antiviral research</Title><ISOAbbreviation>Antiviral Res.</ISOAbbreviation></Journal><ArticleTitle>Inhibitors of SARS-CoV entry--identification using an internally-controlled dual envelope pseudovirion assay.</ArticleTitle><Pagination><MedlinePgn>187-94</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.antiviral.2011.07.016</ELocationID><Abstract><AbstractText>Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) emerged as the causal agent of an endemic atypical pneumonia, infecting thousands of people worldwide. Although a number of promising potential vaccines and therapeutic agents for SARS-CoV have been described, no effective antiviral drug against SARS-CoV is currently available. The intricate, sequential nature of the viral entry process provides multiple valid targets for drug development. Here, we describe a rapid and safe cell-based high-throughput screening system, dual envelope pseudovirion (DEP) assay, for specifically screening inhibitors of viral entry. The assay system employs a novel dual envelope strategy, using lentiviral pseudovirions as targets whose entry is driven by the SARS-CoV Spike glycoprotein. A second, unrelated viral envelope is used as an internal control to reduce the number of false positives. As an example of the power of this assay a class of inhibitors is reported with the potential to inhibit SARS-CoV at two steps of the replication cycle, viral entry and particle assembly. This assay system can be easily adapted to screen entry inhibitors against other viruses with the careful selection of matching partner virus envelopes.</AbstractText><CopyrightInformation>Copyright © 2011 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yanchen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Blood Systems Research Institute, University of California, San Francisco, CA 94118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agudelo</LastName><ForeName>Juliet</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Kai</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Goetz</LastName><ForeName>David H</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>Hansell</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yen Ting</ForeName><Initials>YT</Initials></Author><Author ValidYN="Y"><LastName>Roush</LastName><ForeName>William R</ForeName><Initials>WR</Initials></Author><Author ValidYN="Y"><LastName>McKerrow</LastName><ForeName>James</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Craik</LastName><ForeName>Charles S</ForeName><Initials>CS</Initials></Author><Author ValidYN="Y"><LastName>Amberg</LastName><ForeName>Sean M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Simmons</LastName><ForeName>Graham</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI074986</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI074986-05</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AI074986</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Antiviral Res</MedlineTA><NlmUniqueID>8109699</NlmUniqueID><ISSNLinking>0166-3542</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057166" MajorTopicYN="N">High-Throughput Screening Assays</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014776" MajorTopicYN="N">Virus Cultivation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>05</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>07</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>07</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21820471</ArticleId><ArticleId IdType="pii">S0166-3542(11)00387-1</ArticleId><ArticleId IdType="doi">10.1016/j.antiviral.2011.07.016</ArticleId><ArticleId IdType="pmc">PMC3205982</ArticleId><ArticleId IdType="mid">NIHMS321660</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Biomol Screen. 1999;4(2):67-73</Citation><ArticleIdList><ArticleId IdType="pubmed">10838414</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1994 Sep;68(9):5623-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8057442</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2008 Nov;82(21):10768-75</Citation><ArticleIdList><ArticleId IdType="pubmed">18715909</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antivir Chem Chemother. 2006;17(5):275-84</Citation><ArticleIdList><ArticleId IdType="pubmed">17176632</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2006 Mar 15;346(2):251-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16460775</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2009 Oct 10;393(1):33-41</Citation><ArticleIdList><ArticleId IdType="pubmed">19692105</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 1995 Feb 1;206(2):935-44</Citation><ArticleIdList><ArticleId IdType="pubmed">7531918</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2006 Apr;80(8):4174-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16571833</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Med. 2006 Dec;3(12):e525</Citation><ArticleIdList><ArticleId IdType="pubmed">17194199</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2009 Nov 17;4(11):e7870</Citation><ArticleIdList><ArticleId IdType="pubmed">19924243</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 2006 Feb 10;281(6):3198-203</Citation><ArticleIdList><ArticleId IdType="pubmed">16339146</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2008 Apr;82(7):3220-35</Citation><ArticleIdList><ArticleId IdType="pubmed">18199635</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 2002 Jul 5;277(27):24609-17</Citation><ArticleIdList><ArticleId IdType="pubmed">11986312</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Opin Pulm Med. 2008 May;14(3):248-53</Citation><ArticleIdList><ArticleId IdType="pubmed">18427249</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2011 May 10;413(2):265-74</Citation><ArticleIdList><ArticleId IdType="pubmed">21435673</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2002 Mar;76(5):2518-28</Citation><ArticleIdList><ArticleId IdType="pubmed">11836430</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2007 May;81(9):4694-700</Citation><ArticleIdList><ArticleId IdType="pubmed">17314167</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2011 May;85(9):4122-34</Citation><ArticleIdList><ArticleId IdType="pubmed">21325420</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11876-81</Citation><ArticleIdList><ArticleId IdType="pubmed">16081529</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochemistry. 2007 Jul 31;46(30):8744-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17605471</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Bioorg Med Chem Lett. 1998 Oct 6;8(19):2809-12</Citation><ArticleIdList><ArticleId IdType="pubmed">9873627</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 Oct;79(20):12714-20</Citation><ArticleIdList><ArticleId IdType="pubmed">16188974</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2005 Jun 10;308(5728):1643-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15831716</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2009 Mar;81(3):239-47</Citation><ArticleIdList><ArticleId IdType="pubmed">19118579</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4240-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15010527</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2008 Nov;82(21):10932-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18768973</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001483 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001483 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:21820471
|texte= Inhibitors of SARS-CoV entry--identification using an internally-controlled dual envelope pseudovirion assay.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:21820471" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |